Bone Health

European Medicines Agency Validates Henlius and Organon’s Biosimilar HLX14 for Treating Osteoporosis and Bone Metastasis

Shanghai Henlius Biotech and women’s health pharma company Organon have announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational biosimilar for Prolia and Xgeva (denosumab). This biosimilar aims to provide an alternative treatment for osteoporosis in postmenopausal women at high risk for fractures and for preventing skeletal-related events in patients with bone metastases.…

Hinge Health Adds Movement-Based Menopause Support to Its Digital MSK Clinic

Hinge Health has introduced a new movement-based support program for menopause, specifically designed for those dealing with musculoskeletal (MSK) and pelvic health conditions. This innovative service, now part of Hinge Health’s digital MSK clinic, features a dedicated team of physical therapists who provide customized exercise therapy and lifestyle modifications to help alleviate joint and muscle pain, maintain muscle mass and bone density,…

Solarea Bio Beta Launches Bondia, a Novel Daily Medical Food Helping with Post-Menopausal Bone Loss

Solarea Bio, a US-based clinical-stage biotech company, is pioneering a new approach to bone health management with the beta launch of Bondia. The company is dedicated to leveraging microbial diversity to develop innovative solutions for managing inflammatory diseases. Through its consumer health brand, Journa, the company aims to improve human wellbeing with clinically tested and naturally formulated medical food products. Bondia, a…

Bone Health Technologies Raises $5M to Advance Osteopenia Treatment

Bone Health Technologies (BHT) has recently closed a $5 million funding round to enhance care for individuals with low bone density. This round saw contributions from Esplanade Ventures, Berkeley Catalyst Fund, and Terumo Medical, a global leader in medical technology. The funding arrives at a crucial juncture, with BHT nearing the de novo FDA clearance for its Osteoboost vibration wearable. Osteoboost, designed…

FDA Clears Osteoboost by Bone Health Technologies to Address Osteopenia in Women

Bone Health Technologies, a company at the forefront of bone health solutions, recently announced the FDA clearance of Osteoboost, the first device-based, non-pharmacological prescription treatment for postmenopausal women diagnosed with osteopenia. The wearable belt delivers targeted, calibrated vibration to the lumbar spine and hips, and is designed to reduce the decline in bone strength and density. Osteoboost’s approval introduces a new category…

Bone Health Technologies Receives New Patent for Its Wearable Treatment for Osteoporosis in Post-Menopausal Women 

Healthtech company Bone Health Technologies has recently been awarded its fourth patent, marking a significant milestone in the journey of its product, Osteoboost. The wearable device is at the forefront of addressing osteopenia and osteoporosis in post-menopausal women, two conditions that significantly impact bone health. Osteoboost’s design and innovative approach have made it the first device of its kind to demonstrate a…

OsteoSight Secures FDA Breakthrough Device Designation for X-Ray-Based Bone Mineral Density Assessment

OsteoSight, a new technology designed to utilize subtle signals found in routine X-rays for bone mineral density (BMD) assessment, has received a breakthrough device designation from the Food and Drug Administration (FDA). This achievement has the potential to significantly impact the early identification of osteoporosis and the prevention of fragility fractures. Developed by Naitive Technologies, OsteoSight not only provides automated BMD estimates…

Bone Health Technologies Presents Promising Clinical Trial Data of Wearable Treatment for Osteopenia in Post-Menopausal Women

San Francisco-based Bone Health Technologies (BHT) has presented pivotal trial data for its novel treatment Osteoboost at the renowned endocrinology conference, Endo 2023. The double-blind study enrolled 126 postmenopausal women with low bone mass, focusing on the effectiveness of Osteoboost in reducing the decline of bone strength and density. The Osteoboost device, which is seeking FDA’s Class 2 Prescription De Novo Approval,…